Phase I-II trial of TLK286 (telcyta), carboplatin (C), and paclitaxel (P) as first-line treatment for advanced non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Sequist, L
Fidias, P
Temel, J
Kennedy, E
Ostler, P
Rabin, M
Huberman, M
Keck, J
Brown, G
Lynch, T
机构：
[1] Massachusetts Gen Hosp, Boston, MA 02114 USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[4] Telik Inc, Palo Alto, CA USA
来源：
LUNG CANCER | 2005年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S269 / S269
页数：1
相关论文
共 50 条
  • [41] NAB-PACLITAXEL IN COMBINATION WITH CARBOPLATIN AS FIRST-LINE THERAPY IN DIABETIC PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Hirsh, Vera
    Owen, Scott
    Ko, Amy
    Renschler, Markus F.
    Socinski, Mark A.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S584 - S584
  • [42] Carboplatin plus Weekly Paclitaxel with Bevacizumab for First-line Treatment of Non-small Cell Lung Cancer
    Kubota, Tetsuya
    Okano, Yoshio
    Sakai, Mizu
    Takaoka, Masato
    Tsukuda, Tsukie
    Anabuki, Kazuki
    Kawase, Shigeo
    Miyamoto, Shintaro
    Ohnishi, Hiroshi
    Hatakeyama, Nobuo
    Machida, Hisanori
    Urata, Tomoyuki
    Yamamoto, Akira
    Ogushi, Fumitaka
    Yokoyama, Akihito
    ANTICANCER RESEARCH, 2016, 36 (01) : 307 - 312
  • [43] nab-Paclitaxel (nab-P) plus carboplatin (C) as first-line treatment in patients with advanced non-small cell lung cancer (NSCLC): Clinical outcomes by treatment cycle
    Gridelli, C.
    Li, L.
    O'Brien, M.
    Ong, T. J.
    Pirker, R.
    Socinski, M. A.
    Thomas, M.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S638 - S639
  • [44] A Phase 2 Randomized Trial of Paclitaxel and Carboplatin with or without Panitumumab for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer
    Crawford, Jeffrey
    Swanson, Paul
    Schwarzenberger, Paul
    Sandler, Alan
    Prager, Diane
    Zhang, Kathy
    Freeman, Daniel J.
    Johnson, Carol W.
    Krishnan, Kartik
    Johnson, David
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (12) : 1510 - 1518
  • [45] Randomized phase II trial of weekly squalamine, carboplatin, and paclitaxel as first line therapy for advanced non-small cell lung cancer.
    Rose, V
    Schiller, J
    Wood, A
    Eskander, E
    Holroyd, K
    Desai, A
    Lee, JT
    Ahmed, M
    Kim, B
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 643S - 643S
  • [46] Phase II Study of Paclitaxel, Carboplatin, and Cetuximab as First Line Treatment, for Patients with Advanced Non-small Cell Lung Cancer (NSCLC) Results of OPN-017
    Borghaei, Hossein
    Langer, Corey J.
    Millenson, Michael
    Ruth, Karen J.
    Litwin, Samuel
    Tuttle, Holly
    Seldomridge, Judie Sylvester
    Rovito, Marc
    Mintzer, David
    Cohen, Roger
    Treat, Joseph
    JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (11) : 1286 - 1292
  • [47] Phase 1-2a dose ranging study of TLK286 (Telcyta™, a novel gluthathione analog) in combination with docetaxel in platinum-resistant non-small cell lung cancer (NSCLC).
    Papaclimitrakopoulou, V
    Zinner, R
    Blumenschein, G
    King, L
    Boasberg, P
    Keck, J
    Mascavage, J
    Jameson, A
    Patel, K
    Parra, R
    Brown, GL
    Hanna, N
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6241S - 6241S
  • [48] Randomized Phase II Study of Vandetanib Alone or With Paclitaxel and Carboplatin as First-Line Treatment for Advanced Non-Small-Cell Lung Cancer
    Heymach, John V.
    Paz-Ares, Luis
    De Braud, Filippo
    Sebastian, Martin
    Stewart, David J.
    Eberhardt, Wilfried E. E.
    Ranade, Anantbhushan A.
    Cohen, Graham
    Trigo, Jose Manuel
    Sandler, Alan B.
    Bonomi, Philip D.
    Herbst, Roy S.
    Krebs, Annetta D.
    Vasselli, James
    Johnson, Bruce E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (33) : 5407 - 5415
  • [49] Results of a Phase I/II Trial of Amrubicin (AMR) in Combination with Cisplatin (CDDP) as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
    Hattori, Yoshihiro
    Yamamoto, Nobuyuki
    Ichinose, Yukito
    Negoro, Shunichi
    Hida, Toyoaki
    Takeda, Koji
    Masuda, Noriyuki
    Nakagawa, Kazuhiko
    Yokota, Soichiro
    Fukuoka, Masahiro
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (12) : S386 - S386
  • [50] Results of a phase I/II trial of amrubicin (AMR) in combination with cisplatin (CDDP) as a first-line treatment in patients with advanced non-small cell lung cancer (NSCLC)
    Seto, T.
    Ichinose, Y.
    Yamamoto, N.
    Kaira, K.
    Negoro, S.
    Hida, T.
    Takeda, K.
    Masuda, N.
    Yokota, S.
    Fukuoka, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345